FFC#29/2018

Identification and validation of circulating microvesicles analysis as a new ex vivo assay to monitor cystic fibrosis disease

FFC#29/2018

Identification and validation of circulating microvesicles analysis as a new ex vivo assay to monitor cystic fibrosis disease

PRINCIPAL INVESTIGATOR

Mario Romano (Dip. Scienze Mediche, Orali e Biotecnologiche, Lab. Medicina Molecolare, CeSIMeT Università Chieti-Pescara)

Partner

Paola Lanuti (Dip. Medicina e Scienze dell’Invecchiamento, Lab. Citomorfologia, Università Chieti-Pescara)

RESEARCHERS

14

CATEGORY

AREA 5 Clinical and Epidemiological research

DURATION

2 years

GOAL

€ 55.000 €

RESULTS

37 patients with CF were recruited, 11 of whom were under modulators treatment. Blood samples were taken every 3 months for 21 months and at the beginning and at the end of any respiratory exacerbation. The microvesicles (MV) were counted and their number was proportional to the worsening of the patient’s pulmonary condition and in correlation with the beginning and resolution of the respiratory relapses. Conversely, the number of MV was lower in patients under treatment with modulators in respect of not treated; moreover the higher the number of MV the more serious the respiratory picture. These results need confirmation by increasing the number of subjects, but in any case, the MV count may be of clinical relevance. It will also be necessary the evaluation of the role and the function of MV in the development and evolution of CF pulmonary disease.

OTHER RESULTS

FFC#1/2023

Tezacaftor, one of the components of Kaftrio, induces an accumulation of dihydroceramides both in vitro and in vivo in animal models

FFC#4/2023

Pseudopaline–aztreonam conjugates exhibited enhanced antimicrobial activity against Pseudomonas aeruginosa compared to aztreonam alone

FFC#10/2023

Several drugs already approved for human use inhibit the growth of P. aeruginosa, its virulence, or its ability to form biofilms in vitro